Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Regulatory News (MXCT)

  • There is currently no data for MXCT

Increase to Block Listing

21 Jan 2021 14:49

RNS Number : 5100M
MaxCyte, Inc.
21 January 2021
 

 

 

 

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

 

 

Increase to Block Listing,

 

Block Listing Return

 

and

 

Total Voting Rights

 

 

 

MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company, announces that application has been made for admission to trading on AIM in respect of an additional block listing of 942,900 common stock of $0.01 each in the capital of the Company ("Common Stock") to become effective on 27 January 2021.

 

The Common Stock may be issued pursuant to the exercise of share options under the Company's Long-Term Incentive Plan (the "LTIP") and will, upon issue, rank pari passu in all respects with the Company's existing Common Stock. Following this increase, the total Block Listing will consist of 1,000,000 Common Stock.

 

 

AIM Block Admission Return

 

MaxCyte also makes the following update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies.  

 

a. Name of company

 

MaxCyte, Inc.

 

b. Name of scheme(s)

 

MaxCyte Long Term Incentive Plan

 

c. Period of return:

 

From: 1 July 2020 To: 21 January 2021

 

d. Number and class of securities not issued under scheme

 

319,263 ordinary shares of common stock of $0.01 each

 

e. Number of shares issued under scheme during period

 

262,163 ordinary shares of common stock of $0.01 each

 

f. Balance under the scheme not yet issued at the end of the period.

 

57,100 ordinary shares of common stock of $0.01 each

 

g. Number and class of share(s) (amount of stock / debt securities) originally listed and the date of admission; If additional block listing application have been made, under this scheme, since the original listing application please also state the number of shares and the date(s) of admission.

 

1,000,000 ordinary shares of common stock of $0.01 each on 5 May 2017

 

Please confirm your total issued share capital as at the end of this period.

(If you hold any shares in Treasury state the figure separately);

 

 

The total issued stock capital of the Company is 77,422,169 shares of Common Stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.

The number of unrestricted shares of Common Stock trading under the symbol 'MXCT' is 67,522,080 and the number of restricted shares of Common Stock trading under the symbol 'MXCS' is 9,900,089.  

 

 

Treasury shares (if applicable) ………Nil………….

 

h. Contact name and telephone number for queries;

 

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Accounting Officer

+1 301 944 1660

 

Date

 

21 January 2021

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRPPUMCGUPGGCG
Date   Source Headline
26th Jun 20257:00 amRNSCancellation - Maxcyte Inc
25th Jun 20257:00 amRNSLast Day of Dealings on AIM
23rd Jun 20256:00 pmRNSMaxCyte
19th Jun 20257:00 amRNSResult of Annual General Meeting
12th Jun 20257:00 amRNSHolding(s) in Company
11th Jun 20257:00 amRNS-RMaxCyte and Ori Biotech Announce Collaboration
6th Jun 20259:33 amRNSHolding(s) in Company
5th Jun 20252:16 pmRNSHolding(s) in Company
2nd Jun 20255:14 pmRNSTotal Voting Rights
2nd Jun 20254:17 pmRNSHolding(s) in Company
29th May 20257:06 amRNSHolding(s) in Company
23rd May 20254:52 pmRNSHolding(s) in Company
23rd May 20254:26 pmRNSHolding(s) in Company
23rd May 20257:00 amRNSHolding(s) in Company
19th May 20256:05 pmRNSHolding(s) in Company
16th May 20253:12 pmRNSHolding(s) in Company
9th May 20257:00 amRNSFiling of Form 10-Q
8th May 20257:00 amRNSFirst Quarter 2025 Financial Results
2nd May 20254:40 pmRNSTotal Voting Rights
28th Apr 20257:00 amRNSFiling of definitive proxy statement
22nd Apr 20252:43 pmRNSHolding(s) in Company
22nd Apr 20252:37 pmRNSHolding(s) in Company
15th Apr 20255:00 pmRNSHolding(s) in Company
15th Apr 20257:00 amRNSProposed cancellation of trading on AIM
14th Apr 20259:17 amRNSHolding(s) in Company
10th Apr 20257:00 amRNSMaxCyte to Report Q1 2025 Results on May 7, 2025
8th Apr 20253:35 pmRNSHolding(s) in Company
1st Apr 20255:57 pmRNSTotal Voting Rights
26th Mar 202510:14 amRNSCorrection: Vesting of RSUs and PDMR Dealing
26th Mar 20257:00 amRNSVesting of RSUs and PDMR Dealing
25th Mar 202510:30 amRNSHolding(s) in Company
25th Mar 202510:28 amRNSHolding(s) in Company
25th Mar 202510:26 amRNSHolding(s) in Company
25th Mar 202510:22 amRNSHolding(s) in Company
24th Mar 20259:06 amRNSGrant of Options, RSUs and PSUs and PDMR Dealing
19th Mar 20252:07 pmRNSHolding(s) in Company
12th Mar 20257:01 amRNSFiling of Form 10-K for FY ended December 31, 2024
12th Mar 20257:00 amRNSQ4 & FY 2024 Financial Results
4th Mar 20253:38 pmRNSTotal Voting Rights
19th Feb 20253:23 pmRNSHolding(s) in Company
14th Feb 20255:05 pmRNSHolding(s) in Company
13th Feb 20254:12 pmRNSHolding(s) in Company
13th Feb 20252:52 pmRNSHolding(s) in Company
12th Feb 20257:00 amRNSStrategic Platform License with TG Therapeutics
7th Feb 20257:00 amRNSNotice of Results
4th Feb 20257:00 amRNSTotal Voting Rights
31st Jan 20253:18 pmRNSExercise of options and PDMR dealing
30th Jan 20257:00 amRNSMaxCyte® Acquires SeQure Dx
29th Jan 20253:05 pmRNSHolding(s) in Company
22nd Jan 20252:25 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.